 |
The Journal of Neuroscience, June 13, 2007, 27(24):6428-6435; doi:10.1523/JNEUROSCI.1037-07.2007
Previous Article | Next Article 
Development/Plasticity/Repair
Inhibiting Epidermal Growth Factor Receptor Improves Structural, Locomotor, Sensory, and Bladder Recovery from Experimental Spinal Cord Injury
Matthias Erschbamer,
Karin Pernold, and
Lars Olson
Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
Correspondence should be addressed to Matthias Erschbamer, Department of Neuroscience, Karolinska Institutet, Retzius väg 8, 171 77 Stockholm, Sweden. Email: matthias.erschbamer{at}ki.se
Lack of axon regeneration in the adult CNS has been attributed partly to myelin inhibitors and the properties of astrocytes. After spinal cord injury, proliferating astrocytes not only represent a physical barrier to regenerating axons but also express and secrete molecules that inhibit nerve growth, including chondroitin sulfate proteoglycans (CSPGs). Epidermal growth factor receptor (EGFR) activation triggers astrocytes into becoming reactive astrocytes, and EGFR ligands stimulate the secretion of CSPGs as well as the formation of cribriform astrocyte arrangements that contribute to the formation of glial scars. Recently, it was shown that EGFR inhibitors promote nerve regeneration in vitro and in vivo. Blocking a novel Nogo receptor interacting mechanism and/or effects of EGFR inhibition on astrocytes may underlie these effects. Here we show that rats subjected to weight-drop spinal cord injury can be effectively treated by direct delivery of a potent EGFR inhibitor to the injured area, leading to significantly better functional and structural outcome. Motor and sensory functions are improved and bladder function is restored. The robust effects and the fact that other EGFR inhibitors are in clinical use in cancer treatments make these drugs particularly attractive candidates for clinical trials in spinal cord injury.
Key words: spinal cord injury; astrocytes; functional recovery; bladder function; plasticity; EGFR
Received March 7, 2007;
revised May 7, 2007;
accepted May 7, 2007.
Correspondence should be addressed to Matthias Erschbamer, Department of Neuroscience, Karolinska Institutet, Retzius väg 8, 171 77 Stockholm, Sweden. Email: matthias.erschbamer{at}ki.se
Related articles in J. Neurosci.:
- This Week in The Journal
J. Neurosci. 2007 27: i.
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
M. R. Douglas, K. C. Morrison, S. J. Jacques, W. E. Leadbeater, A. M. Gonzalez, M. Berry, A. Logan, and Z. Ahmed
Off-target effects of epidermal growth factor receptor antagonists mediate retinal ganglion cell disinhibited axon growth
Brain,
November 1, 2009;
132(11):
3102 - 3121.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kumaria
LINGO-1, WNK1, and EGFR: A Hypothesis
J. Biol. Chem.,
September 25, 2009;
284(39):
le9 - le9.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Codeluppi, C. I. Svensson, M. P. Hefferan, F. Valencia, M. D. Silldorff, M. Oshiro, M. Marsala, and E. B. Pasquale
The Rheb-mTOR Pathway Is Upregulated in Reactive Astrocytes of the Injured Spinal Cord
J. Neurosci.,
January 28, 2009;
29(4):
1093 - 1104.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|